Percent change from baseline in spine trabecular BMD by QCT according to testosterone dose

Subjects in cohort 1 received goserelin acetate plus 0 (placebo), 1.25, 2.5, 5, or 10 g of 1% testosterone gel daily. Subjects in cohort 2 received the same treatments plus 1 mg of anastrozole daily. Subjects in cohort 3 received placebos for both goserelin acetate and for the testosterone gel. Note that when anastrozole was administered (ie, cohort 2), the decrease in trabecular BMD was independent of testosterone, indicating that estradiol is the primary regulator of bone density in men.